Purchase this article with an account.
X. Lei, J. Zhang, J. Shen, L. Hu, Y. Wu, L. Mou, G. Xu, W. Li, G.-T. Xu; Erythropoietin Administration Attenuates Pro-Inflammatory Cytokine Production by Müller Cells in Models of Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1988.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the regulatory effects of erythropoietin (EPO) on the production of pro-inflammatory cytokines by Müller cells under the condition of diabetic retinopathy (DR).
In rMC-1, the expression of TNF-α, IL-1β, IL-6 and VEGF were enhanced by 1mM glyoxal. The elevated TNF-α and IL-1β, but not IL-6 and VEGF, were normalized by 2U/ml EPO. Moreover, the transcriptional activity of AP-1, but not NF-ΚB, was influenced by glyoxal and EPO. In early diabetic rats, these pro-inflammatory cytokines except for VEGF were up-regulated. Treatment with EPO (8mU/ per eye) significantly reduced the proteins of TNF-α and IL-1β and moderately attenuated IL-6 production.
These results indicate that in both models of DR EPO attenuates inflammatory response via Müller cells by direct inhibition upon production of TNF-α and IL-1β, which may be due to the suppression of AP-1 activation. In contrast, the expression of IL-6 and VEGF in Müller cells is not regulated by EPO. These findings implicate therapeutic potential of EPO in amelioration of retinal inflammation in DR.
This PDF is available to Subscribers Only